Premiummuscle-building

CJC-1295 DAC

CJC-1295 DAC is a peptide that researchers posit may function similarly to growth hormone-releasing hormone (GHRH), potentially increasing the endogenous production of growth hormone (GH) within the organism. The CJC-1295 DAC peptide is a synthetic 29 amino acid analog of GHRH. It is the shortest functional analog of GHRH that still has the potential capacity to trigger GH release from the somatotroph cells in the pituitary gland. Moreover, 4 of the original 29 amino acids in this fragment are substituted in CJC-1295 DAC, to possibly improve the pharmacokinetics of the peptide and prolong its half-life. The DAC component is a biochemical complex that may further increase the half-life of the peptide. This phenomenon might be ascribed to the alleged capability of the DAC to bind to proteins present in plasma. More precisely, the DAC component appears to entail the attachment of a lysine derivative, identified as N-epsilon-3-maleimidopropionamide, to the C terminus of CJC-1295 DAC. Integrating this modified amino acid sequence with the DAC component might conceivably enhance the pharmacokinetics of CJC-1295 DAC, extending its half-life to approximately 8 days. Simultaneously, it appears to maintain a significant affinity for GHRH receptors, similar to the affinity exhibited by CJC-1295 without DAC. This does not imply that CJC without DAC has no relevance or use in present day research. For example, CJC-1295 without DAC & Ipamorelin blend has been studied for its suggested synergistic potential, as combining GHRH analogs with peptides that appear to activate the ghrelin receptors in the pituitary gland. It is also posited to result in greater GH-synthesis response from the somatotroph cells.

$105.00 USD/ 5mg

Technical Specifications

Technical specifications for CJC-1295 DAC
Sequence	GRF(1-29) analogue with Lys17(εNH-CO-(CH2)2-maleimide)
Molecular Formula	C152H252N44O42
Molecular Weight	3367.95 g/mol
Purity	≥98% (HPLC)
Form	Lyophilized powder
Storage	-20°C, desiccated
CAS	863288-34-0
Also Known As	Tetrasubsituted GRF 1-29 with DAC

Application Areas

Tendon and ligament healing studies

Muscle injury recovery protocols

Gastrointestinal tissue repair research

Anti-inflammatory pathway research

Wound healing research

Veterinary wound healing applications

COA Verified

Fast Shipping

Secure Payment

For Research Use Only. Products are not for human or veterinary consumption. Not a drug, dietary supplement, or medical device. Sold exclusively to qualified research professionals.

Bio-Engineered Precision

Moreover, 4 of the original 29 amino acids in this fragment are substituted in CJC-1295 DAC, to possibly improve the pharmacokinetics of the peptide and prolong its half-life. The DAC component is a biochemical complex that may further increase the half-life of the peptide. This phenomenon might be ascribed to the alleged capability of the DAC to bind to proteins present in plasma.

More precisely, the DAC component appears to entail the attachment of a lysine derivative, identified as N-epsilon-3-maleimidopropionamide, to the C terminus of CJC-1295 DAC. Integrating this modified amino acid sequence with the DAC component might conceivably enhance the pharmacokinetics of CJC-1295 DAC, extending its half-life to approximately 8 days. Simultaneously, it appears to maintain a significant affinity for GHRH receptors, similar to the affinity exhibited by CJC-1295 without DAC.

This does not imply that CJC without DAC has no relevance or use in present day research. For example, CJC-1295 without DAC & Ipamorelin blend has been studied for its suggested synergistic potential, as combining GHRH analogs with peptides that appear to activate the ghrelin receptors in the pituitary gland. It is also posited to result in greater GH-synthesis response from the somatotroph cells.

Purity Level≥98% (HPLC)

Molecular Weight3367.95 g/mol

Molecular FormulaC152H252N44O42

SequenceGRF(1-29) analogue with Lys17(εNH-CO-(CH2)2-maleimide)

CJC-1295 DAC Peptide Mechanism of Action

conducted two clinical studies in 2006 to examine the action of CJC-1295 DAC. In the first study, CJC-1295 DAC or a placebo was presented in one of four ascending concentrations. In the second study, CJC-1295 DAC was presented repeatedly at a single concentration.

Proposed Mechanism

According to the results, after the introduction of CJC-1295 DAC, there appeared to be an increase in GH and insulin-like growth factor-1 (IGF-I) levels among the research models. CJC-1295 DAC is thought to elevate levels of IGF-1 by increasing growth hormone production, which in turn may bind to receptors on liver cells, potentially triggering a cascade of intracellular signaling processes. This binding might activate the Janus kinase-signal transducer and activator of the transcription (JAK-STAT) signaling pathway.

Key Observations

Subsequently, the activated STAT proteins might migrate to the nucleus, where they may attach to specific DNA sequences considered to be response elements, potentially resulting in the transcription of the IGF-I gene. It is theorized that the IGF-I produced in liver cells may be transported to various target tissues. Additionally, it is believed that many tissues possess GH receptors, which, upon activation, may lead to the production of IGF-I within the tissues themselves.

Key Findings

IGF-I is considered a potent hormone that may play a key role in promoting growth, suggesting it mediates many growth and anabolic effects of growth hormone. It is hypothesized to encourage cell growth and proliferation, as well as the enlargement and strengthening of tissues and organs, possibly aiding in protein synthesis and cellular expansion. Preliminary exposure to CJC-1295 DAC in experimental models has been suggested to significantly affect average growth hormone levels, with studies reporting an apparent increase of 2- to 10-fold for 6 days or possibly longer.

CJC-1295 DAC Peptide Half-life

JC-1295 DAC Peptide Half-life In its original form, CJC-1295 DAC uses a technology referred to as Drug Affinity Complex (DAC). Contrary to GHRH, which is considered to boast a half-life of approximately 7 minutes, researchers report CJC-1295 without DAC to exhibit a longer half-life of 30 minutes due to its truncated 29 amino acid fragment, and 4 of the original amino acids in this fragment are replaced. Alterations to the peptide structure, specifically at the 2nd, 8th, 15th, and 27th amino acid positions, are thought to potentially improve the peptide's stability against breakdown by the enzyme dipeptidyl peptidase-4.

Proposed Mechanism

These alterations are detailed as follows: At the 2nd position, L-alanine is substituted by D-alanine, a change believed to bolster resistance against enzymatic degradation. At the 8th position, asparagine is replaced with glutamine, a modification that might reduce the risk of asparagine rearrangement and amide hydrolysis. The substitution of glycine with alanine at the 15th position is theorized to enhance the peptide's bioactivity.

Key Observations

The alteration from methionine to leucine at the 27th position is considered to potentially prevent methionine oxidation. These modifications aim to enhance the peptide's resilience and functional efficacy by mitigating enzymatic degradation and improving stability under physiological conditions. In addition, the half-life of the peptide appears to be additionally extended to

CJC-1295 DAC Peptide Ancillary Studies

CJC-1295 DAC Peptide Ancillary Studies In 2005, a clinical study aimed to evaluate the mechanism of action of CJC-1295 DAC in models of immunodeficiency virus (HIV) associated with visceral obesity. In this study, the models would be presented with CJC-1295 DAC for 3 months, followed by a 6-week follow-up period. However, this study was terminated during recruitment, and no related results were posted.

Proposed Mechanism

According to a 2009 Norwegian study, a compound was submitted for analysis to evaluate whether it contained prohibited substances or not. The researchers of the Norwegian Doping Control Laboratory and School of Pharmacy reported that this substance was CJC-1295 DAC. In their published article they concluded that "

Key Observations

CJC-1295 DAC is a releasing factor for growth hormone ". CJC-1295 DAC peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

[1]
Henninge J, Pepaj M, Hullstein I, Hemmersbach P. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2010 Nov-Dec;2(11-12):647-650. DOI: 10.1002/dta.233 . Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005 Jul;146(7):3052-8. doi: 10.1210/en.2004-1286. Epub 2005 Apr 7. PMID: 15817669.
[2]
Sinha DK, Balasubramanian A, Tatem AJ, Rivera-Mirabal J, Yu J, Kovac J, Pastuszak AW, Lipshultz LI. Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males. Transl Androl Urol. 2020 Mar;9(Suppl 2):S149-S159. doi: 10.21037/tau.2019.11.30. PMID: 32257855; PMCID: PMC7108996.
[3]
Steiger A, Holsboer F. Neuropeptides and human sleep. Sleep. 1997 Nov;20(11):1038-52. PMID: 9456470.
[4]
Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006 Mar;91(3):799-805. doi: 10.1210/jc.2005-1536 . Epub 2005 Dec 13. PMID: 16352683.
[5]
Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006 Dec;91(12):4792-7. doi: 10.1210/jc.2006-1702 . Epub 2006 Oct 3. PMID: 17018654.
[6]
Martin, B., Lopez de Maturana, R., Brenneman, R., Walent, T., Mattson, M. P., & Maudsley, S. (2005). Class II G protein-coupled receptors and their ligands in neuronal function and protection. Neuromolecular medicine , 7 (1-2), 3–36https://doi.org/10.1385/nmm:7:1-2:003
[7]
Newton, A. C., Bootman, M. D., & Scott, J. D. (2016). Second Messengers. Cold Spring Harbor perspectives in biology , 8 (8), a005926https://doi.org/10.1101/cshperspect.a005926
[8]
Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1290-4. doi: 10.1152/ajpendo.00201.2006 . Epub 2006 Jul 5. PMID: 16822960.
[9]
Van Hout MC, Hearne E. Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. Subst Use Misuse. 2016 Jan 2;51(1):73-84. doi: 10.3109/10826084.2015.1082595 . Epub 2016 Jan 15. PMID: 26771670. ClinicalTrials.gov, A service of the US National Institutes of Health. Available at:http://clinicaltrials.gov/ct2/show/NCT00267527

Certificates & Testing

Batch-level purity documentation

Every P3X Labs batch is independently tested by a third-party laboratory. COA documents confirm purity, identity, and absence of contaminants. Lot-specific COAs are linked to each shipment via QR code on the vial label.

COA: assigned at fulfillment — scan QR on vial

HPLC tested

Mass spectrometry verified

≥99% purity guaranteed